Changing the Drug Delivery System: Does It Add to Non-Compliance Ramifications Control? A Simulation Study on the Pharmacokinetics and Pharmacodynamics of Atypical Antipsychotic Drug

Changing the Drug Delivery System: Does It Add to Non-Compliance Ramifications Control? A Simulation Study on the Pharmacokinetics and Pharmacodynamics of Atypical Antipsychotic Drug

This study investigates the pharmacokinetic (PK) and pharmacodynamic (PD) consequences of shifting from Quetiapine fumarate immediate-release (IR) to extended-release (XR) formulation in non-adherent schizophrenia patients. Monte-Carlo simulations using population PK and PD models were implemented t...

Full description

Bibliographic Details
Main Author:	Mohammed H. Elkomy
Format:	Article
Language:	English
Published:	MDPI AG 2020-03-01
Series:	Pharmaceutics
Subjects:	antipsychotic schizophrenia pharmacokinetic/pharmacodynamic modeling compliance monte carlo simulations extended-release
Online Access:	https://www.mdpi.com/1999-4923/12/4/297

Similar Items

The Pharmacodynamics of Antipsychotic Drugs in Women and Men
by: Mary V. Seeman
Published: (2021-04-01)

Pharmacokinetic/pharmacodynamic comparison between generic and brand-name levofloxacin based on Monte Carlo simulation
by: Pan Ma, et al.
Published: (2023-06-01)

Evaluating the efficacy of different antibiotics against Neisseria gonorrhoeae: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation
by: Jiaojiao Zhong, et al.
Published: (2024-01-01)

Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation
by: O. Asuphon, et al.
Published: (2016-09-01)

Concept and utility of population pharmacokinetic and pharmacokinetic/pharmacodynamic models in drug development and clinical practice
by: Roganović Maša, et al.
Published: (2021-01-01)

Prediction of marbofloxacin dosage for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida by pharmacokinetic/pharmacodynamic modelling
by: Lucy Dorey, et al.
Published: (2017-07-01)

Pharmacokinetic/Pharmacodynamic Analysis and Dose Optimization of Cefmetazole and Flomoxef against Extended-Spectrum β-Lactamase-Producing <i>Enterobacterales</i> in Patients with Invasive Urinary Tract Infection Considering Renal Function
by: Yukihiro Hamada, et al.
Published: (2022-03-01)

A temporo-spatial pharmacometabolomics method to characterize pharmacokinetics and pharmacodynamics in the brain microregions by using ambient mass spectrometry imaging
by: Dan Liu, et al.
Published: (2022-08-01)

Pharmacokinetics and pharmacodynamics of linezolid in plasma/cerebrospinal fluid in patients with cerebral hemorrhage after lateral ventricular drainage by Monte Carlo simulation
by: Wu X, et al.
Published: (2018-06-01)

Optimizing tylosin dosage for co-infection of Actinobacillus pleuropneumoniae and Pasteurella multocida in pigs using pharmacokinetic/pharmacodynamic modeling
by: Eon-Bee Lee, et al.
Published: (2023-09-01)

Pharmacokinetic and pharmacodynamic modeling of oral mitiglinide on glucose lowering in healthy Chinese volunteers
by: Shijia Liu, et al.
Published: (2017-07-01)

Metabolic disturbances in patients with paranoid schizophrenia treated with atypical antipsychotic drugs
by: Leonid Mikhaylovich Bardenshteyn, et al.
Published: (2010-06-01)

Pharmacokinetics and Pharmacodynamics: A Comprehensive Analysis of the Absorption, Distribution, Metabolism, and Excretion of Psychiatric Drugs
by: Zainab Zakaraya, et al.
Published: (2024-02-01)

Study on consequences for interaction of myricetin with canagliflozin: A special attention to pharmacokinetics and pharmacodynamics of drug
by: Naga Raju Kandukoori, et al.
Published: (2023-01-01)

Ivermectin: Difficulties in resolving pharmacokinetic and pharmacodynamic relationships in onchocerciasis
by: E N Shu, et al.
Published: (2004-01-01)

Pharmacogenetics of Long-Term Outcomes of Schizophrenia Spectrum Disorders: The Functional Role of CYP2D6 and CYP2C19
by: Amrit K. Sandhu, et al.
Published: (2023-09-01)

Pharmacokinetic–Pharmacodynamic Model for the Testosterone-Suppressive Effect of Leuprolide in Normal and Prostate Cancer Rats
by: Dong-Seok Lee, et al.
Published: (2018-04-01)

Pharmacokinetic and pharmacodynamic drug-drug interaction of Nomilin with atorvastatin in hyperlipidemic mice
by: Yan Ding, et al.
Published: (2023-11-01)

Competence Mining of Vancomycin (VAN) in the Management of Infections Due to Bacterial Strains With High VAN Minimum Inhibitory Concentrations (MICs): A Novel Dosing Strategy Based on Pharmacokinetic/Pharmacodynamic Modeling
by: Xiangqing Song, et al.
Published: (2021-04-01)

Pharmacodynamics and pharmacokinetics of nalbuphine in xylazine‑sedated horses
by: Amal Hammad, et al.
Published: (2023-05-01)

Pharmacodynamics of Five Anthraquinones (Aloe-emodin, Emodin, Rhein, Chysophanol, and Physcion) and Reciprocal Pharmacokinetic Interaction in Rats with Cerebral Ischemia
by: Rong-Rong Li, et al.
Published: (2019-05-01)

Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients
by: Alexandre Le Marouille, et al.
Published: (2021-10-01)

Potential pharmacokinetic and pharmacodynamic herb-drug interactions of Andrographis paniculata (Burm. f.) and andrographolide: A systematic review
by: Elza Sundhani, et al.
Published: (2022-04-01)

PHARMACOKINETICS AND PHARMACODYNAMICS OF DRUGS IN PATIENTS WITH RENAL DYSFUNCTION
by: K. Zakon, et al.
Published: (2017-12-01)

Computer-aided drug design and in silico pharmacokinetics predictions of some potential antipsychotic agents
by: Sabitu Babatunde Olasupo, et al.
Published: (2021-07-01)

Pharmacokinetic–pharmacodynamic analysis of cefmetazole against extended-spectrum β-lactamase-producing Enterobacteriaceae in dogs using Monte Carlo Simulation
by: Mizuki Kusumoto, et al.
Published: (2023-09-01)

Tigecycline Pharmacokinetic and Pharmacodynamic Profile in Patients with Chronic Obstructive Pulmonary Disease Exacerbation
by: Maria Kipourou, et al.
Published: (2023-02-01)

Atypical antipsychotics in the treatment of schizophrenia
by: Swiss Medical Weekly
Published: (2003-02-01)

Pharmacokinetic and Pharmacodynamic Drug–Drug Interactions: Research Methods and Applications
by: Lei Sun, et al.
Published: (2023-07-01)

Pharmacokinetic and pharmacodynamic correlation of plasma concentrations and blood pressure in hypertensive patients: A study
by: Mahvash Iram, et al.
Published: (2016-01-01)

Clozapine: A special case of an atypical antipsychotic
by: Elina Marinho
Published: (2024-04-01)

Pharmacokinetic and Pharmacodynamic Properties of Rosmarinic Acid in Rat Cholestatic Liver Injury
by: Jianbin Min, et al.
Published: (2018-09-01)

Pharmacodynamics and pharmacokinetics interaction between nefopam and tramadol in the broiler chicks model
by: Yaareb J. Mousa, et al.
Published: (2022-04-01)

A strategy for designing voriconazole dosage regimens to prevent invasive pulmonary aspergillosis based on a cellular pharmacokinetics/pharmacodynamics model
by: Taotao Wang, et al.
Published: (2018-06-01)

Real-World Analysis of Potential Pharmacokinetic and Pharmacodynamic Drug Interactions with Apixaban in Patients with Non-Valvular Atrial Fibrillation
by: Badreldin HA, et al.
Published: (2020-07-01)

Atypical Antipsychotics Induced Metabolic Syndrome
by: Aysegul Demirel, et al.
Published: (2015-03-01)

Influence of aprepitant on the pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits
by: Raghunandan Reddy Kura, et al.
Published: (2018-05-01)

Isavuconazole Pharmacokinetics and Pharmacodynamics in Children
by: Hirsh Elhence, et al.
Published: (2022-12-01)

New and Old Horizons for an Ancient Drug: Pharmacokinetics, Pharmacodynamics, and Clinical Perspectives of Dimethyl Fumarate
by: Paolinelli Matteo, et al.
Published: (2022-12-01)

Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development
by: Zaloumis Sophie, et al.
Published: (2012-08-01)